CDT Equity Inc. (NASDAQ:CDT) Short Interest Update

CDT Equity Inc. (NASDAQ:CDT) was the target of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 129,934 shares, a drop of 26.9% from the February 26th total of 177,766 shares. Currently, 6.3% of the company’s shares are sold short. Based on an average trading volume of 107,627 shares, the short-interest ratio is presently 1.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CDT Equity stock. Apollon Wealth Management LLC acquired a new position in shares of CDT Equity Inc. (NASDAQ:CDT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 107,454 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned 28.28% of CDT Equity as of its most recent SEC filing. Hedge funds and other institutional investors own 3.29% of the company’s stock.

CDT Equity Stock Performance

Shares of CDT stock opened at $7.85 on Friday. The firm’s 50 day moving average price is $21.44 and its two-hundred day moving average price is $55.72. CDT Equity has a 52-week low of $7.45 and a 52-week high of $4,200.00. The stock has a market cap of $706,500.00, a PE ratio of 0.00 and a beta of 1.84.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.